<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001965525</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001612042</issuerCik>
      <issuerName>Ascendis Pharma A/S</issuerName>
      <secFileNumber>001-36815</secFileNumber>
      <issuerAddress>
        <com:street1>TUBORG BOULEVARD 12</com:street1>
        <com:city>HELLERUP</com:city>
        <com:stateOrCountry>P7</com:stateOrCountry>
        <com:zipCode>1105 BP</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>45 70 22 22 44</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>IMANI SIHAM</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>ORDINARY SHARES</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>CITIGROUP GLOBAL MARKETS</name>
        <address>
          <com:street1>390 GREENWICH ST</com:street1>
          <com:city>NEW YORK</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10013</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>1800</noOfUnitsSold>
      <aggregateMarketValue>435762.00</aggregateMarketValue>
      <noOfUnitsOutstanding>61977408</noOfUnitsOutstanding>
      <approxSaleDate>03/02/2026</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>ORDINARY SHARES</securitiesClassTitle>
      <acquiredDate>03/02/2026</acquiredDate>
      <natureOfAcquisitionTransaction>RESTRICTED STOCK VESTING</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>ASCENDIS PHARMA A/S</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>2773</amountOfSecuritiesAcquired>
      <paymentDate>03/02/2026</paymentDate>
      <natureOfPayment>COMPENSATION</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks> SECTION 3D BASED ON INDICATIVE MARKET PRICE 242.09. SHARES BEING SOLD FOR THE VESTING AND SETTLEMENT OF EQUITY AWARDS. UNDER SECURITIES TO BE SOLD DATE ACQUIRED ARE VARIOUS DATES.THE INTENDED NUMBER OF SHARES IS AN APPRROXIMATION DUE TO MARKET CONDITIONS. SALES ARE BEING PERFORMED OVER MULTIPLE DAYS.THESE ARE NON DISCRETIONARY TRANSACTIONS. THESE ARE BEING PERFORMED UNDER AN ESTABLISHED 10B51 PLAN</remarks>
    <noticeSignature>
      <noticeDate>03/02/2026</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>09/05/2024</planAdoptionDate>
      </planAdoptionDates>
      <signature>CONFORMED SIGNATURE ON FILE</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
